<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05117996</url>
  </required_header>
  <id_info>
    <org_study_id>RC21_123</org_study_id>
    <nct_id>NCT05117996</nct_id>
  </id_info>
  <brief_title>Simplified Bowel Preparation Versus Standard Bowel Preparation Before Capsule Endoscopy in Patients With Crohn's Disease</brief_title>
  <acronym>CROHN-PREP</acronym>
  <official_title>Simplified Bowel Preparation Versus Standard Bowel Preparation Before Capsule Endoscopy in Patients With Crohn's Disease: a Prospective Randomized Controlled Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The European guidelines currently recommend to use 2 L of polyethylene glycol and free&#xD;
      residue diet before any capsule endoscopy. However, up to now, no studies have been conducted&#xD;
      to specifically evaluate bowel preparation modalities before small bowel capsule endoscopy in&#xD;
      patients with Crohn's disease.&#xD;
&#xD;
      In patients with Crohn's disease and small bowel ulcers, polyethylene glycol may remove some&#xD;
      fibrin from these ulcers and alter bowel preparation. Moreover, it is important to select the&#xD;
      most acceptable bowel preparation because patients with Crohn's disease will have to repeat&#xD;
      capsule endoscopy several times after initiating treatment, for monitoring under treatment,&#xD;
      or for detection of post-operative recurrence.&#xD;
&#xD;
      In a preliminary retrospective study, it has been suggested that a simplified bowel&#xD;
      preparation with liquid diet the evening before and water on the morning of the capsule&#xD;
      endoscopy induced a better bowel preparation than the standard method with polyethylene&#xD;
      glycol.&#xD;
&#xD;
      Thus, the aim of the study is to demonstrate the superiority of this simplified bowel&#xD;
      preparation compared to the standard preparation modality in terms of quality of bowel&#xD;
      preparation, patient's acceptability and diagnostic yield.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Crohn's disease is a chronic inflammatory bowel disease characterized by the presence of&#xD;
      ulcers that can affect the entire digestive tract, from the mouth to the anus. The existence&#xD;
      of small bowel lesions is pejorative and associated with poorer outcomes and a higher risk of&#xD;
      intestinal resection.&#xD;
&#xD;
      Small bowel capsule endoscopy allows the visualization of the entire small bowel in a&#xD;
      non-invasive and outpatient setting, without any anesthesia. It is the exam with the best&#xD;
      diagnostic yield for the detection of small bowel ulcers in patients with Crohn's disease.&#xD;
      Moreover, it allows the monitoring of patients after initiating treatment to assess mucosal&#xD;
      healing and the detection of post-operative recurrence.&#xD;
&#xD;
      As for any endoscopic examinations, its acceptability depends on bowel preparation&#xD;
      modalities. The European Society of Gastrointestinal Endoscopy (ESGE) currently recommends to&#xD;
      use 2 L of polyethylene glycol and free residue diet before any capsule endoscopy. However,&#xD;
      patients with Crohn's disease were a minority (&lt; 1.5 %) in the studies on which these&#xD;
      guidelines are based on.&#xD;
&#xD;
      Yet, in patients with small bowel Crohn's disease, polyethylene glycol may remove some fibrin&#xD;
      from the ulcers and hence, alter bowel preparation. Moreover, it is important to select the&#xD;
      most acceptable bowel preparation because patients with Crohn's disease will have to repeat&#xD;
      capsule endoscopy several times after initiating treatment, for monitoring under treatment,&#xD;
      or for detection of post-operative recurrence.&#xD;
&#xD;
      A preliminary retrospective study suggested that a simplified bowel preparation with liquid&#xD;
      diet the evening before and water on the morning of the capsule endoscopy induced a better&#xD;
      bowel preparation than the standard method with polyethylene glycol.&#xD;
&#xD;
      Thus, the aim of CROHN-PREP study is to demonstrate the superiority of this simplified bowel&#xD;
      preparation compared to the standard preparation modality in terms of quality of bowel&#xD;
      preparation, patient's acceptability and diagnostic yield.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Single blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>KODA score (entire small bowel)</measure>
    <time_frame>through the reading of the capsule endoscopy, an average of 6 months</time_frame>
    <description>Small bowel preparation quality (entire small bowel)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>KODA score for each small bowel segment</measure>
    <time_frame>through the reading of the capsule endoscopy, an average of 6 months</time_frame>
    <description>Small bowel preparation quality (by segment : upper/middle/lower third)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative assessment by the reader</measure>
    <time_frame>through the reading of the capsule endoscopy, an average of 6 months</time_frame>
    <description>Proportion of images in which preparation is considered as &quot;good&quot;, &quot;moderate&quot; or &quot;low&quot; by the reader (by segment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative assessment of acceptability of preparation</measure>
    <time_frame>Immediately before the capsule endoscopy</time_frame>
    <description>Patient's acceptability of the bowel preparation on a visual analog scale between 0 (nil) to 10 (excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative assessment on a visual analog scale between 0 (nil) to 10 (excellent)</measure>
    <time_frame>Immediately before the capsule endoscopy</time_frame>
    <description>Patient's acceptability of the examination on a visual analog scale between 0 (nil) to 10 (excellent)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lewis score</measure>
    <time_frame>through the reading of the capsule endoscopy, an average of 6 months</time_frame>
    <description>Diagnostic yield evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete examinations</measure>
    <time_frame>through the reading of the capsule endoscopy, an average of 6 months</time_frame>
    <description>Percentage of complete examinations defined by the visualization of the first duodenal image and the first caecal image</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small bowel transit time</measure>
    <time_frame>through the reading of the capsule endoscopy, an average of 6 months</time_frame>
    <description>Recording time between the visualization of the first duodenal image and the first caecal image, if visualized</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Crohn Disease</condition>
  <arm_group>
    <arm_group_label>Standard small bowel preparation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 L of polyethylene glycol and free residue diet the day before the capsule endoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simplified small bowel preparation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liquid diet the evening before and water on the morning of the capsule endoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>capsule endoscopy</intervention_name>
    <description>capsule endoscopy</description>
    <arm_group_label>Simplified small bowel preparation</arm_group_label>
    <arm_group_label>Standard small bowel preparation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard small bowel preparation</intervention_name>
    <description>2 L of polyethylene glycol and free residue diet the day before the capsule endoscopy</description>
    <arm_group_label>Standard small bowel preparation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Simplified small bowel preparation</intervention_name>
    <description>Liquid diet the evening before and water on the morning of the capsule endoscopy</description>
    <arm_group_label>Simplified small bowel preparation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Patients of both genders aged over 18 years old&#xD;
&#xD;
          -  With an established diagnosis of Crohn's disease, whether active or quiescent&#xD;
&#xD;
          -  With an indication of a small bowel capsule endoscopy&#xD;
&#xD;
          -  Without any small bowel stricture (patency capsule procedure on the 7 days before the&#xD;
             capsule endoscopy)&#xD;
&#xD;
          -  Registered with a social security scheme&#xD;
&#xD;
          -  Having provided their oral consent for the study after appropriate information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Patients aged below 18 years old&#xD;
&#xD;
          -  Diagnosis of ulcerative colitis or IBD unclassified&#xD;
&#xD;
          -  Presence of an ileostomy&#xD;
&#xD;
          -  Presence of a small bowel syndrome&#xD;
&#xD;
          -  Symptoms suggestive of a small bowel stricture&#xD;
&#xD;
          -  Retention of the patency capsule on an abdominal X-ray performed 48 hours after the&#xD;
             ingestion&#xD;
&#xD;
          -  Abdominal pain after the ingestion of the patency capsule&#xD;
&#xD;
          -  Planned abdominal surgery in the next month&#xD;
&#xD;
          -  Known intestinal fistula&#xD;
&#xD;
          -  Swallowing disorders&#xD;
&#xD;
          -  Established diagnosis of delayed gastric emptying or suggestive symptoms&#xD;
&#xD;
          -  Intake of non-steroidal anti-inflammatory drugs (NSAIDs) in the month prior to the&#xD;
             capsule endoscopy&#xD;
&#xD;
          -  Intake of oral iron supplementation in the week prior to the capsule endoscopy&#xD;
&#xD;
          -  Intake of oral 5-ASA granules in the week prior to the capsule endoscopy&#xD;
&#xD;
          -  Ongoing pregnancy&#xD;
&#xD;
          -  Presence of a pace-maker or implantable defibrillator&#xD;
&#xD;
          -  Known allergy to polyethylene glycol or to lactose&#xD;
&#xD;
          -  Vulnerable people i.e. adults under a legal protection regime (guardianship,&#xD;
             trusteeship, judicial safeguard)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Angers University Hospital</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nina DIB</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brest University hospital</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Franck CHOLET</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cholet hospital</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mehdi Kaasis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vend√©e departmental hospital</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Astrid DE MAISSIN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine LE BERRE</last_name>
    </contact>
    <investigator>
      <last_name>Arnaud BOURREILLE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rennes University hospital</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Guillaume BOUGUEN</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

